In contrast, treatment of RA synovial explants with tofacitinib in vitro inhibited the production of IL-6, TNFα and other pro-inflammatory cytokines, as well as of MMP1, and decreased the invasive properties of SF [37]. The gene discussed is TNF; the disease is rheumatoid arthritis.